Results 81 to 90 of about 80,955 (206)
Abstract SY29-02: Novel mechanisms of PARP inhibitor resistance
, 2017 Large-scale genomic studies have demonstrated that approximately 50% of high-grade serous ovarian cancers (HGSOCs) harbor genetic and epigenetic alterations in homologous recombination repair (HRR) pathway genes.
Alan D. D'Andrea
core +1 more source
First PARP Inhibitor Ok'd for Breast Cancer
, 2018 The FDA has approved olaparib, a PARP inhibitor, for use in patients with metastatic breast cancer who also carry a germline BRCA1 or BRCA2 mutation.
core +1 more source
NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression [PDF]
, 2019 ADP-ribosylation is a unique posttranslational modification catalyzed by poly(ADP-ribose) polymerases (PARPs) using NAD+ as ADP-ribose donor. PARPs play an indispensable role in DNA damage repair and small molecule PARP inhibitors have emerged as potent ...
Luo, Tao +9 more
core +1 more source
PARP Inhibitors for Cancer Therapy
Cell, 2017 Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations.
Ken Y, Lin, W Lee, Kraus
openaire +2 more sources
Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging
EJNMMI Radiopharmacy and ChemistryBackground Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a promising class of therapeutics, particularly in the treatment of cancers with defective DNA repair mechanisms, such as those with breast cancer genes (BRCA) mutations.
Gianluca Destro +4 more
doaj +1 more source
, 2013 (A) Effects of PARP inhibitor on the Akt1 protein, and phosphorylation of Akt1 and GSK-3 β in control and transplanted kidneys determined using immunoblotting with protein and phospho-specific primary antibodies.
Peter Degrell (318151) +6 more
core +1 more source
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity [PDF]
, 2019 Treatment of cancer with poly (ADP-ribose) polymerase (PARP) inhibitors is currently limited to cells defective in the homologous recombination (HR) pathway.
Chien, Jeremy +3 more
core +1 more source
PARP inhibitors are not all equal [PDF]
Cancer Biology & Therapy, 2013 To many investigators PARP1 is simply a substrate for caspase 3, and whose cleavage is thought indicative of apoptosis. However, in reality PARP1 plays a major role in the biology of the cell cycle and DNA repair. (1)(,) (2) PARP1 binds to damaged DNA where it becomes enzymatically activated and ADP ribosylates itself and other proteins.
openaire +2 more sources
Frontiers in PharmacologyBackgroundThe landscape of poly (ADP-ribose) polymerase (PARP) inhibitor treatment for ovarian cancer (OC) is continually evolving. This research aimed to evaluate the efficacy and safety of PARP inhibitors compared to placebo as a maintenance therapy ...
Guojuan Sun, Yi Liu
doaj +1 more source
Basic research of PARP inhibitor effects for chemotherapy induced mucositis [PDF]
研究成果の概要（和文）：本研究では、CDDPとPARP阻害剤のマウスへの投与が腸管粘膜と腸内細菌叢に及ぼす影響を検証した。C57BL/6メスを4群（CDDP群、PARP阻害剤群、併用群、コントロール群）に分け、腹腔内注射を行い、1・3・6か月目に解析を行った。体重は1ヶ月目にCDDP群と併用群で減少したが、3・6か月目には回復した。生存率はCDDP群で40日目までに減少し、200日後に併用群で低下した。消化管粘膜では、CDDP群では絨毛が有意に短縮、併用群ではコントロール群との有意差も認められなかった ...
80396746 +4 more
core